Key result
Evidence from multiple study designs supports the hypothesis that omega-3 fatty acid deficiency is a preventable risk factor for coronary heart disease comorbidity in major depressive disorder.
Why the study?
Does omega-3 fatty acid supplementation reduce coronary heart disease comorbidity and mortality in patients with major depressive disorder?
Does omega-3 fatty acid supplementation reduce coronary heart disease comorbidity and mortality in patients with major depressive disorder?
Omega-3 fatty acid deficiency may be a preventable risk factor for coronary heart disease comorbidity in patients with major depressive disorder, warranting future intervention studies.
Hypothesis-generating for omega-3 supplementation in MDD; randomized trials needed before clinical adoption.
Major depression disorder (MDD) significantly increases the risk for coronary heart disease (CHD) which is a leading cause of mortality in patients with MDD. Moreover, depression is frequently observed in a subset of patients following acute coronary syndrome (ACS) and increases risk for mortality. Here evidence implicating omega-3 (n-3) fatty acid deficiency in the pathoaetiology of CHD and MDD is reviewed, and the hypothesis that n-3 fatty acid deficiency is a preventable risk factor for CHD comorbidity in MDD patients is evaluated. This hypothesis is supported by cross-national and cross-sectional epidemiological surveys finding an inverse correlation between n-3 fatty acid status and prevalence rates of both CHD and MDD, prospective studies finding that lower dietary or membrane EPA+DHA levels increase risk for both MDD and CHD, case-control studies finding that the n-3 fatty acid status of MDD patients places them at high risk for emergent CHD morbidity and mortality, meta-analyses of controlled n-3 fatty acid intervention studies finding significant advantage over placebo for reducing depression symptom severity in MDD patients, and for secondary prevention of cardiac events in CHD patients, findings that n-3 fatty acid status is inversely correlated with other documented CHD risk factors, and patients diagnosed with MDD after ACS exhibit significantly lower n-3 fatty acid status compared with nondepressed ACS patients. This body of evidence provides strong support for future studies to evaluate the effects of increasing dietary n-3 fatty acid status on CHD comorbidity and mortality in MDD patients.
No takes yet. Share an insight, caveat, or question.
Robert K. McNamara (2009) conducted a review in Major depressive disorder and coronary heart disease. Omega-3 fatty acid deficiency was evaluated. Evidence from multiple study designs supports the hypothesis that omega-3 fatty acid deficiency is a preventable risk factor for coronary heart disease comorbidity in major depressive disorder.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: